ArticleMedicine2026
Efficacy of HALP combined with T2-weighted MRI radiomics in predicting pathological complete response and overall survival in rectal cancer after neoadjuvant chemoradiotherapy: A retrospective single-center study in China.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
This study aimed to develop and validate an integrated model combining pretreatment hemoglobin, albumin, lymphocyte, platelet (HALP) score and T2-weighted magnetic resonance imaging radiomics for predicting pathological complete response (pCR) and overall survival in patients with locally advanced rectal cancer (LARC) undergoing neoadjuvant chemoradiotherapy. A total of 137 consecutive LARC patients from January 2019 to January 2022 were retrospectively included. Pretreatment 3.0T T2-weighted high-resolution magnetic resonance imaging scans were performed. Four stable features were selected using least absolute shrinkage and selection operator regression. The HALP score was calculated as (hemoglobin × albumin × lymphocytes)/platelets, with an optimal cutoff of 48.4 determined by X-tile analysis. Three predictive models were constructed: a radiomics-only model (RAD), a HALP-only model (HALP), and a combined model (RAD + HALP) using a random forest classifier. Model performance was assessed using the area under the curve (AUC), sensitivity, specificity, calibration curves, and decision curve analysis. The pCR rate was 13.1% (18/137). For pCR prediction, the combined model achieved an AUC of 0.808 (95% confidence interval: 0.73-0.88), compared to 0.788 for the RAD model. The HALP score alone did not show predictive capability (P = .59). For overall survival prediction, the combined model significantly outperformed the individual models, with an AUC of 0.957 (sensitivity: 0.945, specificity: 1.0; DeLong test, P = .002), the AUC was corrected to 0.852 (sensitivity: 0.788, specificity: 0.889; P < .001). Multivariate Cox analysis identified HALP as an independent prognostic factor (hazard ratio: 5.83, 95% confidence interval: 2.23-15.2). The combined RAD + HALP model demonstrated excellent and internally validated performance in predicting both short-term treatment response and long-term survival in LARC patients undergoing neoadjuvant chemoradiotherapy patients. Prospective multicenter studies are warranted prior to clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.